0001193125-23-014676.txt : 20230125 0001193125-23-014676.hdr.sgml : 20230125 20230125060403 ACCESSION NUMBER: 0001193125-23-014676 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230125 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230125 DATE AS OF CHANGE: 20230125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elevance Health, Inc. CENTRAL INDEX KEY: 0001156039 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] IRS NUMBER: 352145715 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16751 FILM NUMBER: 23549634 BUSINESS ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 BUSINESS PHONE: 8003311476 MAIL ADDRESS: STREET 1: 220 VIRGINIA AVENUE CITY: INDIANAPOLIS STATE: IN ZIP: 46204 FORMER COMPANY: FORMER CONFORMED NAME: Anthem, Inc. DATE OF NAME CHANGE: 20141202 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT, INC DATE OF NAME CHANGE: 20100105 FORMER COMPANY: FORMER CONFORMED NAME: WELLPOINT INC DATE OF NAME CHANGE: 20041130 8-K 1 d418386d8k.htm 8-K 8-K
false 0001156039 0001156039 2023-01-25 2023-01-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2023

 

 

Elevance Health, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Indiana   001-16751   35-2145715

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

220 Virginia Ave

Indianapolis, IN 46204

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (833) 401-1577

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock   ELV   NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On January 25, 2023, Elevance Health, Inc. issued a press release reporting its financial results for the quarter ended December 31, 2022. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

None of the information furnished in Item 2.02 or Exhibit 99.1 hereto shall be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

No.

   

Exhibit

99.1    Press Release, dated January 25, 2023, reporting Elevance Health, Inc. financial results for the quarter ended December 31, 2022.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

FORWARD-LOOKING STATEMENTS

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not undertake to update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including healthcare laws and regulations, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to comply with any privacy or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated with providing pharmacy benefit management (“PBM”), healthcare and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint

ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 25, 2023

 

ELEVANCE HEALTH, INC.
By:  

/s/ Kathleen S. Kiefer

Name:   Kathleen S. Kiefer
Title:   Corporate Secretary
 EX-99.1 2 d418386dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

PRESS RELEASE

 

LOGO

ELEVANCE HEALTH REPORTS FOURTH QUARTER

AND FULL YEAR 2022 RESULTS

 

  •  

Fourth quarter and full year GAAP net income was $3.93 and $24.81 per share

 

  •  

Fourth quarter and full year adjusted net income was $5.23* and $29.07* per share

 

  •  

Full year operating revenue grew 13.7% year-over-year to $156 billion

 

  •  

Full year operating gain grew 12.9% year-over-year to $8.5 billion

 

  •  

Medical enrollment increased 2.2 million members year-over-year to 47.5 million members

 

  •  

Quarterly dividend increased by 16% to $1.48 per share

Indianapolis, Ind. - January 25, 2023 - Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2022 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjusted earnings per share.

“We made considerable progress in our transformation to become a lifetime, trusted health partner in 2022,” said Gail K. Boudreaux, President and CEO. “Through strategic advancements we are making to optimize our health benefits businesses, invest in high growth opportunities, and accelerate capabilities and services, we are delivering on our commitments to our communities and all of our stakeholders. Additionally, we look forward to welcoming Blue Cross and Blue Shield of Louisiana to Elevance Health to further this commitment within a 15th Blue state. Last year marked the fifth consecutive year in which we met or exceeded our long-term adjusted earnings per share growth target, and we are well-positioned to do it again in 2023.”

The Company expects GAAP net income to be greater than $29.80 per share in 2023, and adjusted net income to be greater than $32.60 per share.

 

*

Refer to GAAP reconciliation tables on page 14.

 

1

CONSOLIDATED HIGHLIGHTS

Earnings Per Share: GAAP net income was $3.93 per share in the fourth quarter, including net negative adjustment items of $1.30 per share. Adjusted net income was $5.23* per share. Full year GAAP net income was $24.81 per share, including net negative adjustment items of $4.26 per share. Adjusted net income was $29.07* per share.

 

*

Please refer to the GAAP reconciliation tables on page 14.

Membership: Medical membership totaled approximately 47.5 million as of December 31, 2022, an increase of 2.2 million, or 4.8 percent year-over-year. Government Business membership increased by 1.1 million year-over-year driven primarily by growth in the Medicaid business and organic growth in Medicare Advantage. Commercial & Specialty Business membership increased by 1.1 million year-over-year, driven primarily by strong sales to fee-based employers.

During the fourth quarter of 2022, medical membership increased by 248 thousand driven by organic growth in Medicaid, which we attribute primarily to the suspension of eligibility recertification, as well as the acquisition of Vivida Health, which added 29 thousand Medicaid members.

Operating Revenue: Operating revenue was $39.7 billion in the fourth quarter of 2022, an increase of $3.6 billion, or 10.1 percent year-over-year. Operating revenue was $155.7 billion for the full year, representing 13.7 percent growth over 2021. The increase in both the quarter and the full year was driven by higher premium revenue due to membership growth in Medicaid, growth in Medicare Advantage, as well as premium rate increases to cover overall cost trends. The increase in operating revenue was further attributable to growth in pharmacy product revenue within CarelonRx driven by growth in consumers served and higher utilization of prescription drugs.

Benefit Expense Ratio: The benefit expense ratio was 89.4 percent in the fourth quarter of 2022, a decrease of 10 basis points year-over-year. The decrease was driven by the realignment of certain quality improvement costs to match recent regulatory clarifications. Excluding the realignment, our benefit expense ratio would have increased, driven by the non-recurrence of favorable out of period adjustment items in Medicaid in the prior year quarter, partially offset by improved medical underwriting performance in our Commercial & Specialty business. The benefit expense ratio was 87.4 percent for the full year of 2022, a decrease of 10 basis points year-over-year. The decrease was primarily driven by the realignment of certain quality improvement costs. Excluding the realignment, the full year benefit expense ratio would have increased, driven by a shift in business mix toward Medicaid, which carries a higher benefit expense ratio than our commercial and Medicare health plans.

Medical claims reserves established at December 31, 2021 developed in line with the Company’s expectations as of the fourth quarter of 2022.

 

2

Days in Claims Payable: Days in Claims Payable was 47.7 days as of December 31, 2022, unchanged from September 30, 2022 and an increase of 2.5 days compared to December 31, 2021.

SG&A Expense Ratio: The SG&A expense ratio was 11.5 percent in the fourth quarter of 2022, a decrease of 20 basis points from 11.7 percent in the fourth quarter of 2021. For the full year of 2022, the SG&A expense ratio was 11.4 percent, a decrease of 20 basis points from 11.6 percent in 2021. The decrease for both the quarter and the full year was primarily driven by operating expense leverage associated with growth in operating revenue and lower business optimization charges taken in 2022 as compared to 2021, partially offset by increased spend to support growth in operations and the realignment of certain quality improvement expenses previously reported in benefit expense in the prior year periods.

Operating Cash Flow: Operating cash flow was a use of $1.5 billion, or (1.6) times net income in the fourth quarter of 2022, a decrease of $3.2 billion as compared to the prior year quarter. The year-on-year decrease was driven by the early receipt of premium payments from the Centers for Medicare and Medicaid in third quarter of 2022, which were received during the fourth quarter in 2021. For the full year 2022, operating cash flow was $8.4 billion, or 1.4 times net income.

Share Repurchase Program: During the fourth quarter of 2022, the Company repurchased 1.1 million shares of its common stock for $567 million, at a weighted average price of $497.24. For the full year of 2022, the Company repurchased 4.8 million shares of its common stock for $2.3 billion, at a weighted average price of $478.99. As of December 31, 2022, the Company had approximately $1.9 billion of Board-approved share repurchase authorization remaining.

On January 24, 2023, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5.0 billion increase to the common stock repurchase program. The Company intends to utilize this authorization over a multi-year period, subject to market and industry conditions.

Cash Dividend: During the fourth quarter of 2022, the Company paid a quarterly dividend of $1.28 per share, representing a distribution of cash totaling $305 million.

On January 24, 2023, the Audit Committee of the Company’s Board of Directors declared a first quarter 2023 dividend to shareholders of $1.48 per share, an increase of 16 percent from the quarterly dividend payment in the fourth quarter. On an annualized basis, the new quarterly dividend equates to $5.92 per share. The first quarter dividend is payable on March 24, 2023, to shareholders of record at the close of business on March 10, 2023.

Investment Portfolio & Capital Position: During the fourth quarter of 2022, the Company recorded net losses of $111 million. During the fourth quarter of 2021, the Company recorded net gains of $211 million. These amounts are excluded from adjusted earnings per share.

As of December 31, 2022, the Company’s net unrealized loss position in the investment portfolio was $2.3 billion, consisting primarily of fixed maturity securities. As of December 31, 2022, cash and investments at the parent company totaled approximately $1.2 billion.

 

3

REPORTABLE SEGMENTS

Elevance Health has four reportable segments: Commercial & Specialty Business (comprised of Individual, Group risk-based, Group fee-based, and BlueCard businesses); Government Business (comprised of the Medicaid, Medicare, and Federal Health Products & Services businesses); CarelonRx (formerly IngenioRx); and Other (comprised of the Carelon companies, formerly known as our Diversified Business Group, and corporate expenses not allocated to our other reportable segments).

 

Elevance Health, Inc.  
Reportable Segment Highlights  
(Unaudited)  
(In millions)    Three Months Ended December 31     Twelve Months Ended December 31  
     2022     2021     Change     2022     2021     Change  

Operating Revenue

             

Commercial & Specialty Business

    $ 10,350     $ 9,905       4.5 %    $ 41,674     $ 38,809       7.4 % 

Government Business

      24,646       21,912       12.5 %      96,810       82,919       16.8 % 

CarelonRx

      7,523       6,801       10.6 %      28,526       25,431       12.2 % 

Other

      3,410       2,693       26.6 %      13,294       10,250       29.7 % 

Eliminations

      (6,262)       (5,293)       18.3 %      (24,644)       (20,466)       20.4 % 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total Operating Revenue1

    $ 39,667     $ 36,018       10.1 %    $ 155,660     $ 136,943       13.7 % 

Operating Gain (Loss)2

             

Commercial & Specialty Business

    $ 260     $ 74       251.4 %    $ 2,933     $ 2,753       6.5 % 

Government Business

      644       748       (13.9) %      3,297       3,061       7.7 % 

CarelonRx

      475       427       11.2 %      1,868       1,684       10.9 % 

Other

      (11)       (61)       NM       354       (9)       NM  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total Operating Gain1

    $ 1,368     $ 1,188       15.2 %    $ 8,452     $ 7,489       12.9 % 

Operating Margin

             

Commercial & Specialty Business

      2.5 %      0.7 %      180 bp       7.0 %      7.1 %      (10) bp  

Government Business

      2.6 %      3.4 %      (80) bp       3.4 %      3.7 %      (30) bp  

CarelonRx

      6.3 %      6.3 %      — bp       6.5 %      6.6 %      (10) bp  

Total Operating Margin1

      3.4 %      3.3 %      10 bp       5.4 %      5.5 %      (10) bp  

 

1.

See “Basis of Presentation” on page 6 herein.

2.

Operating gain for the three and twelve months ended December 31, 2022 included $39 of charges related to business optimization plans; including $20 for Commercial & Specialty Business; $16 for the Government Business; and $3 for the Other segment. Operating gain for the three and twelve months ended December 31, 2021 included $187 of charges related to business optimization plans; including $106 for Commercial & Specialty Business; $47 for the Government Business; $2 for CarelonRx; and $32 for the Other segment.

Commercial & Specialty Business: Operating gain in the Commercial & Specialty Business segment totaled $260 million in the fourth quarter of 2022, an increase of $186 million from $74 million in the fourth quarter of 2021. The increase was primarily driven by improved medical underwriting performance in our commercial risk-based business and lower business optimization expenses in the fourth quarter of 2022 as compared to the fourth quarter of 2021.

Government Business: Operating gain in the Government Business segment was $644 million in the fourth quarter of 2022, a decrease of $104 million from $748 million in the fourth quarter of 2021. The decrease was primarily driven by the non-recurrence of certain favorable out of period rate actions in Medicaid in the prior year quarter partially offset by increased gross profit in our Medicare health plans and lower business optimization expenses in the fourth quarter of 2022 as compared to the fourth quarter of 2021.

 

4

CarelonRx: Operating gain was $475 million in the fourth quarter of 2022, an increase of $48 million from $427 million in the fourth quarter of 2021. The increase was driven by higher prescription volumes associated with growth in integrated medical and standalone pharmacy customers.

Other: The Company reported an operating loss of $11 million in the Other segment for the fourth quarter of 2022, an improvement of $50 million from an operating loss of $61 million in the prior year quarter, driven by growth in Carelon’s affiliated and unaffiliated earnings.

 

5

Basis of Presentation

 

1.

Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Refer to page 14 for the GAAP reconciliation tables.

 

2.

Operating margin is defined as operating gain divided by operating revenue.

Conference Call and Webcast

Management will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time (“EDT”) to discuss the company’s fourth quarter results and outlook. The conference call should be accessed at least 15 minutes prior to the start of the call with the following numbers:

 

888-947-9963 (Domestic)

    800-396-1242 (Domestic Replay)

312-470-0178 (International)

    203-369-3272 (International Replay)

The access code for today’s conference call is 3972058. There is no access code for the replay. The replay will be available from 11:30 a.m. EDT today, until the end of the day on February 24, 2023. The call will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A webcast replay will be available following the call.

 

Elevance Health Contacts:   
Investor Relations    Media
Stephen Tanal    Leslie Porras
Stephen.Tanal@elevancehealth.com    Leslie.Porras@elevancehealth.com

 

6

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of humanity. The company supports consumers, families, and communities across the entire care journey – connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s companies serve approximately 119 million people through a diverse portfolio of industry-leading medical, digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.

 

7

Elevance Health, Inc.

Membership Summary

(Unaudited and in Thousands)

 

                          Change from  

Medical Membership

    December 31,
2022		      December 31,
2021		      September 30,
2022		      December 31,
2021		     September 30,
2022		  

Commercial & Specialty Business

              

Individual

      789        759        800        4.0 %      (1.4 )% 

Group Risk-Based

      3,988        4,006        3,988        (0.4 )%      —   % 
  

 

 

     

 

 

     

 

 

       

Commercial Risk-Based

      4,777        4,765        4,788        0.3 %      (0.2 )% 

BlueCard®

      6,462        6,178        6,453        4.6 %      0.1 % 

Group Fee-Based

      20,174        19,395        20,184        4.0 %      —   % 
  

 

 

     

 

 

     

 

 

       

Commercial Fee-Based

      26,636        25,573        26,637        4.2 %      —   % 
  

 

 

     

 

 

     

 

 

       

Total Commercial & Specialty Business

      31,413        30,338        31,425        3.5 %      —   % 

Government Business

              

Medicare Advantage

      1,977        1,859        1,969        6.3 %      0.4 % 

Medicare Supplement

      947        952        945        (0.5 )%      0.2 % 
  

 

 

     

 

 

     

 

 

       

Total Medicare

      2,924        2,811        2,914        4.0 %      0.3 % 

Medicaid

      11,571        10,600        11,319        9.2 %      2.2 % 

Federal Employees Health Benefits

      1,623        1,625        1,625        (0.1 )%      (0.1 )% 
  

 

 

     

 

 

     

 

 

       

Total Government Business

      16,118        15,036        15,858        7.2 %      1.6 % 
  

 

 

     

 

 

     

 

 

       

Total Medical Membership

      47,531        45,374        47,283        4.8 %      0.5 % 
  

 

 

     

 

 

     

 

 

       

Other Membership

              

Life and Disability Members

      4,834        4,782        4,796        1.1 %      0.8 % 

Dental Members

      6,692        6,674        6,655        0.3 %      0.6 % 

Dental Administration Members

      1,586        1,491        1,577        6.4 %      0.6 % 

Vision Members

      9,813        8,031        9,628        22.2 %      1.9 % 

Medicare Part D Standalone Members

      271        438        274        (38.1 )%      (1.1 )% 

 

8

Elevance Health, Inc.

Consolidated Statements of Income

(Unaudited)

 

(In millions, except per share data)    Three Months Ended
December 31		        
     2022     2021     Change  

Revenues

       

Premiums

    $ 33,646     $ 30,769       9.4 % 

Product revenue

      4,137       3,525       17.4 % 

Administrative fees and other revenue

      1,884       1,724       9.3 % 
  

 

 

    

 

 

    

Total operating revenue

      39,667       36,018       10.1 % 

Net investment income

      373       352       6.0 % 

Net (losses) gains on financial instruments

      (111 )      211       (152.6 )% 
  

 

 

    

 

 

    

Total revenues

      39,929       36,581       9.2 % 

Expenses

       

Benefit expense

      30,091       27,538       9.3 % 

Cost of products sold

      3,646       3,070       18.8 % 

Selling, general and administrative expense

      4,562       4,222       8.1 % 

Interest expense

      229       200       14.5 % 

Amortization of other intangible assets

      247       135       83.0 % 

Loss on extinguishment of debt

      —         16       (100.0 )% 
  

 

 

    

 

 

    

Total expenses

      38,775       35,181       10.2 % 
  

 

 

    

 

 

    

Income before income tax expense

      1,154       1,400       (17.6 )% 

Income tax expense

      193       275       (29.8 )% 
  

 

 

    

 

 

    

Net income

      961       1,125       (14.6 )% 

Net (income) loss attributable to noncontrolling interests

      (12 )      12       NM  
  

 

 

    

 

 

    

Shareholders’ net income

    $ 949     $ 1,137       (16.5 )% 
  

 

 

    

 

 

    

Shareholders’ net income per diluted share

    $ 3.93     $ 4.63       (15.1 )% 
  

 

 

    

 

 

    

Diluted shares

      241.2       245.5       (1.8 )% 

Benefit expense as a percentage of premiums

      89.4 %      89.5 %      (10 )bp 

Selling, general and administrative expense as a percentage of total operating revenue

      11.5 %      11.7 %      (20 )bp 

Income before income tax expense as a percentage of total revenue

      2.9 %      3.8 %      (90 )bp 

“NM” = calculation not meaningful

 

9

Elevance Health, Inc.

Consolidated Statements of Income

(Unaudited)

 

(In millions, except per share data)    Twelve Months Ended
December 31		        
     2022     2021     Change  

Revenues

       

Premiums

    $ 133,229     $ 117,373       13.5 % 

Product revenue

      14,978       12,657       18.3 % 

Administrative fees and other revenue

      7,453       6,913       7.8 % 
  

 

 

    

 

 

    

Total operating revenue

      155,660       136,943       13.7 % 

Net investment income

      1,485       1,378       7.8 % 

Net (losses) gains on financial instruments

      (550 )      318       (273.0 )% 
  

 

 

    

 

 

    

Total revenues

      156,595       138,639       13.0 % 

Expenses

       

Benefit expense

      116,487       102,645       13.5 % 

Cost of products sold

      13,035       10,895       19.6 % 

Selling, general and administrative expense

      17,686       15,914       11.1 % 

Interest expense

      851       798       6.6 % 

Amortization of other intangible assets

      767       441       73.9 % 

Loss on extinguishment of debt

      —         21       (100.0 )% 
  

 

 

    

 

 

    

Total expenses

      148,826       130,714       13.9 % 
  

 

 

    

 

 

    

Income before income tax expense

      7,769       7,925       (2.0 )% 

Income tax expense

      1,750       1,830       (4.4 )% 
  

 

 

    

 

 

    

Net income

      6,019       6,095       (1.2 )% 

Net loss attributable to noncontrolling interests

      6       9       NM  
  

 

 

    

 

 

    

Shareholders’ net income

    $ 6,025     $ 6,104       (1.3 )% 
  

 

 

    

 

 

    

Shareholders’ net income per diluted share

    $ 24.81     $ 24.73       0.3 % 
  

 

 

    

 

 

    

Diluted shares

      242.8       246.8       (1.6 )% 

Benefit expense as a percentage of premiums

      87.4 %      87.5 %      (10 )bp 

Selling, general and administrative expense as a percentage of total operating revenue

      11.4 %      11.6 %      (20 )bp 

Income before income tax expense as a percentage of total revenue

      5.0 %      5.7 %      (70 )bp 

“NM” = calculation not meaningful

 

10

Elevance Health, Inc.

Consolidated Balance Sheets

 

(In millions)    December 31,
2022		     December 31,
2021		  

Assets

      (Unaudited )   

Current assets:

     

Cash and cash equivalents

    $ 7,387     $ 4,880  

Fixed maturity securities

      25,952       26,267  

Equity securities

      953       1,881  

Premium receivables

      7,083       5,681  

Self-funded receivables

      4,663       4,010  

Other receivables

      4,298       3,749  

Other current assets

      5,281       4,654  
  

 

 

    

 

 

  

Total current assets

      55,617       51,122  

Long-term investments:

     

Fixed maturity securities

      752       632  

Other invested assets

      5,685       5,225  

Property and equipment, net

      4,316       3,919  

Goodwill

      24,383       24,228  

Other intangible assets

      10,315       10,615  

Other noncurrent assets

      1,704       1,719  
  

 

 

    

 

 

  

Total assets

    $ 102,772     $ 97,460  
  

 

 

    

 

 

  

Liabilities and equity

     

Liabilities

     

Current liabilities:

     

Medical claims payable

    $ 15,596     $ 13,518  

Other policyholder liabilities

      6,505       5,521  

Unearned income

      1,112       1,153  

Accounts payable and accrued expenses

      5,035       4,970  

Short-term borrowings

      265       275  

Current portion of long-term debt

      1,500       1,599  

Other current liabilities

      9,683       7,849  
  

 

 

    

 

 

  

Total current liabilities

      39,696       34,885  

Long-term debt, less current portion

      22,349       21,157  

Reserves for future policy benefits

      737       802  

Deferred tax liabilities, net

      2,034       2,805  

Other noncurrent liabilities

      1,562       1,683  
  

 

 

    

 

 

  

Total liabilities

      66,378       61,332  
  

 

 

    

 

 

  

Shareholders’ equity

     

Common stock

      2       2  

Additional paid-in capital

      9,084       9,148  

Retained earnings

      29,724       27,088  

Accumulated other comprehensive loss

      (2,503 )      (178 ) 
  

 

 

    

 

 

  

Total shareholders’ equity

      36,307       36,060  

Noncontrolling interests

      87       68  
  

 

 

    

 

 

  

Total equity

      36,394       36,128  
  

 

 

    

 

 

  

Total liabilities and equity

    $ 102,772     $ 97,460  
  

 

 

    

 

 

  

 

11

Elevance Health, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

(In millions)    Twelve Months Ended December 31  
     2022     2021  

Operating activities

     

Net income

    $ 6,019     $ 6,095  

Adjustments to reconcile net income to net cash provided by operating activities:

     

Net losses (gains) on financial instruments

      550       (318 ) 

Equity in net earnings of other invested assets

      (293 )      (562 ) 

Depreciation and amortization

      1,675       1,302  

Deferred income taxes

      (76 )      326  

Impairment of property and equipment

      7       73  

Share-based compensation

      264       255  

Changes in operating assets and liabilities:

     

Receivables, net

      (2,510 )      (2,138 ) 

Other invested assets

      11       (70 ) 

Other assets

      120       37  

Policy liabilities

      2,826       2,597  

Unearned income

      (42 )      (113 ) 

Accounts payable and other liabilities

      252       719  

Income taxes

      (338 )      140  

Other, net

      (66 )      21  
  

 

 

    

 

 

  

Net cash provided by operating activities

      8,399       8,364  

Investing activities

     

Purchases of investments

      (24,946 )      (18,669 ) 

Proceeds from sale of investments

      11,988       10,269  

Maturities, calls and redemptions from investments

      10,620       4,344  

Changes in securities lending collateral

      (301 )      (956 ) 

Purchases of subsidiaries, net of cash acquired

      (649 )      (3,476 ) 

Purchases of property and equipment

      (1,152 )      (1,087 ) 

Other, net

      (120 )      (63 ) 
  

 

 

    

 

 

  

Net cash used in investing activities

      (4,560 )      (9,638 ) 

Financing activities

     

Net (repayments of) proceeds from commercial paper borrowings

      (300 )      50  

Net proceeds from (repayments of) short-term borrowings

      (10 )      275  

Net proceeds from long-term borrowings

      1,172       2,394  

Changes in securities lending payable

      302       956  

Changes in bank overdrafts

      933       (376 ) 

Repurchase and retirement of common stock

      (2,316 )      (1,900 ) 

Cash dividends

      (1,229 )      (1,104 ) 

Proceeds from issuance of common stock under employee stock plans

      182       203  

Taxes paid through withholding of common stock under employee stock plans

      (93 )      (102 ) 

Other, net

      41       27  
  

 

 

    

 

 

  

Net cash (used in) provided by financing activities

      (1,318 )      423  

Effect of foreign exchange rates on cash and cash equivalents

      (14 )      (10 ) 
  

 

 

    

 

 

  

Change in cash and cash equivalents

      2,507       (861 ) 

Cash and cash equivalents at beginning of period

      4,880       5,741  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 7,387     $ 4,880  
  

 

 

    

 

 

  

 

12

Elevance Health, Inc.

Reconciliation of Medical Claims Payable

 

     Years Ended December 31  
     2022     2021     2020  
(In millions)    (Unaudited)              

Gross medical claims payable, beginning of year

    $ 13,282     $ 11,135     $ 8,647  

Ceded medical claims payable, beginning of year

      (21 )      (46 )      (33 ) 
  

 

 

    

 

 

    

 

 

  

Net medical claims payable, beginning of year

      13,261       11,089       8,614  
  

 

 

    

 

 

    

 

 

  

Business combinations and purchase adjustments

      133       420       339  

Net incurred medical claims:

       

Current year

      113,414       100,440       85,094  

Prior years redundancies(1)

      (869 )      (1,703 )      (637 ) 
  

 

 

    

 

 

    

 

 

  

Total net incurred medical claims

      112,545       98,737       84,457  
  

 

 

    

 

 

    

 

 

  

Net payments attributable to:

       

Current year medical claims

      98,997       88,156       74,629  

Prior years medical claims

      11,600       8,829       7,692  
  

 

 

    

 

 

    

 

 

  

Total net payments

      110,597       96,985       82,321  

Net medical claims payable, end of year

      15,342       13,261       11,089  

Ceded medical claims payable, end of year

      6       21       46  
  

 

 

    

 

 

    

 

 

  

Gross medical claims payable, end of year*

    $ 15,348     $ 13,282     $ 11,135  
  

 

 

    

 

 

    

 

 

  

Current year medical claims paid as a percentage of current year net incurred medical claims

      87.3 %      87.8 %      87.7 % 

Prior year redundancies in the current year as a percentage of prior year net medical claims payable less prior year redundancies in the current year

      7.0 %      18.1 %      8.0 % 

Prior year redundancies in the current year as a percentage of prior year net incurred medical claims

      0.9 %      2.0 %      0.8 % 

 

(1) 

Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for amounts less than originally estimated.

*

Excludes insurance lines other than short duration.

 

13

Elevance Health, Inc.

GAAP Reconciliation

(Unaudited)

Elevance Health, Inc. has referenced “Adjusted Net Income” and “Adjusted Net Income Per Share,” which are non-GAAP measures, in this document. These non-GAAP measures are not intended to be alternatives to any measure calculated in accordance with GAAP. In addition to these non-GAAP measures, references are made to the measures “Operating Revenue” and “Operating Gain.” Each of these measures is provided to further aid investors in understanding and analyzing the company’s core operating results and comparing Elevance Health, Inc.’s financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income herein. A reconciliation of the non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP, together with a reconciliation of reportable segments operating gain to income before income tax expense, is reported below. Prior amounts may be grouped differently to conform to current presentation.

 

     Three Months Ended
December 31		           Twelve Months Ended
December 31		        
(In millions, except per share data)    2022     2021     Change     2022     2021     Change  

Shareholders’ net income

    $ 949     $ 1,137       (16.5 )%    $ 6,025     $ 6,104       (1.3 )% 

Add / (Subtract):

             

Net losses (gains) on financial instruments

      111       (211 )        550       (318 )   

Amortization of other intangible assets

      247       135         767       441    

Loss on extinguishment of debt

      —         16         —         21    

Business optimization charges

      39       187         39       187    

BCBSA litigation settlement

      (20 )      —           (44 )      —      

Transaction and integration related costs

      36       19         72       54    

Litigation expenses

      1       27         12       42    

Tax impact of non-GAAP adjustments

      (102 )      (49 )        (363 )      (120 )   
  

 

 

    

 

 

      

 

 

    

 

 

    

Net adjustment items

      312       124         1,033       307    
  

 

 

    

 

 

      

 

 

    

 

 

    

Adjusted shareholders’ net income

    $ 1,261     $ 1,261       —   %    $ 7,058     $ 6,411       10.1 % 
  

 

 

    

 

 

      

 

 

    

 

 

    

Shareholders’ net income per diluted share

    $ 3.93     $ 4.63       (15.1 )%    $ 24.81     $ 24.73       0.3 % 

Add / (Subtract):

             

Net losses (gains) on financial instruments

      0.46       (0.86 )        2.27       (1.29 )   

Amortization of other intangible assets

      1.02       0.55         3.16       1.79    

Loss on extinguishment of debt

      —         0.07         —         0.09    

Business optimization charges

      0.16       0.76         0.16       0.76    

BCBSA litigation settlement

      (0.08 )      —           (0.18 )      —      

Transaction and integration related costs

      0.15       0.08         0.30       0.22    

Litigation expenses

      —         0.11         0.05       0.17    

Tax impact of non-GAAP adjustments

      (0.42 )      (0.20 )        (1.50 )      (0.49 )   

Rounding impact

      0.01       —           —         —      
  

 

 

    

 

 

      

 

 

    

 

 

    

Net adjustment items

      1.30       0.51         4.26       1.25    
  

 

 

    

 

 

      

 

 

    

 

 

    

Adjusted shareholders’ net income per diluted share

    $ 5.23     $ 5.14       1.8 %    $ 29.07     $ 25.98       11.9 % 
  

 

 

    

 

 

      

 

 

    

 

 

    
                 Full Year 2023 Outlook        

Shareholders’ net income per diluted share

          Greater than $29.80    

Add / (Subtract):

         

Amortization of other intangible assets

            Approximately $3.63    

Tax impact of non-GAAP adjustments

            Approximately $(0.83)    
        

 

 

    

Net adjustment items

          Approximately $2.80    
        

 

 

    

Adjusted shareholders’ net income per diluted share

          Greater than $32.60    
        

 

 

    
     Three Months Ended
December 31		           Twelve Months Ended
December 31		        
(In millions)    2022     2021     Change     2022     2021     Change  

Income before income tax expense

    $ 1,154     $ 1,400       (17.6 )%    $ 7,769     $ 7,925       (2.0 )% 

Net investment income

      (373 )      (352 )        (1,485 )      (1,378 )   

Net losses (gains) on financial instruments

      111       (211 )        550       (318 )   

Interest expense

      229       200         851       798    

Amortization of other intangible assets

      247       135         767       441    

Loss on extinguishment of debt

      —         16         —         21    
  

 

 

    

 

 

      

 

 

    

 

 

    

Reportable segments operating gain

    $ 1,368     $ 1,188       15.2 %    $ 8,452     $ 7,489       12.9 % 
  

 

 

    

 

 

      

 

 

    

 

 

    

 

14

2022 QUARTERLY & ANNUAL RESULTS - PRO-FORMA FOR

NEW REPORTABLE SEGMENTS

Beginning in 2023, Elevance Health will have four reportable segments: Health Benefits, the combination of our existing Commercial & Specialty Business and Government Business (comprised of Individual, Group risk-based, Group fee-based, BlueCard businesses, Medicaid, Medicare, and Federal Health Products & Services businesses); CarelonRx (formerly IngenioRx); Carelon Services, carved out from our existing Other segment (formerly known as Diversified Business Group); and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not allocated to our other reportable segments).

Elevance Health, Inc.

Reportable Segment Highlights

(Unaudited)

 

(In millions)    1Q 2022     2Q 2022     3Q 2022     4Q 2022     2022  

Operating Revenue

           

Health Benefits

    $ 34,027     $ 34,396     $ 35,065     $ 34,996     $ 138,484  

Carelon2

      9,631       10,054       10,403       10,715       40,803  

Corporate & Other

      273       315       211       218       1,017  

Eliminations

      (6,045 )      (6,283 )      (6,054 )      (6,262 )      (24,644 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total Operating Revenue1

    $ 37,886     $ 38,482     $ 39,625     $ 39,667     $ 155,660  

Operating Gain (Loss)3

           

Health Benefits

    $ 1,871     $ 1,802     $ 1,653     $ 904     $ 6,230  

Carelon2

      598       592       641       492       2,323  

Corporate & Other

      (22 )      (27 )      (24 )      (28 )      (101 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

  

Total Operating Gain1

    $ 2,447     $ 2,367     $ 2,270     $ 1,368     $ 8,452  

Operating Margin

           

Health Benefits

      5.5 %      5.2 %      4.7 %      2.6 %      4.5 % 

Carelon

      6.2 %      5.9 %      6.2 %      4.6 %      5.7 % 

Total Operating Margin1

      6.5 %      6.2 %      5.7 %      3.4 %      5.4 % 
(In millions)    1Q 2022     2Q 2022     3Q 2022     4Q 2022     2022  

Carelon Services - Consumers Served

      104.0       104.7       105.3       105.0       105.0  

CarelonRx Adjusted Scripts

      73.0       76.4       76.9       82.0       308.3  

 

1.

See “Basis of Presentation” on page 6 herein.

2.

Operating Revenue and Operating Gain for Carelon for the three months ended March 31, 2022 included $6,683 and $398 for CarelonRx; $2,948 and $200 for Carelon Services, respectively. Operating Revenue and Operating Gain for Carelon for the three months ended June 30, 2022 included $7,071 and $479 for CarelonRx; $2,983 and $113 for Carelon Services, respectively. Operating Revenue and Operating Gain for Carelon for the three months ended September 30, 2022 included $7,249 and $516 for CarelonRx; $3,154 and $125 for Carelon Services, respectively. Operating Revenue and Operating Gain for Carelon for the three months ended December 31, 2022 included $7,523 and $475 for CarelonRx; $3,192 and $17 for Carelon Services, respectively. Operating Revenue and Operating Gain for Carelon for the twelve months ended December 31, 2022 included $28,526 and $1,868 for CarelonRx; $12,277 and $455 for Carelon Services, respectively.

3.

Operating Gain for the three and twelve months ended December 31, 2022 included $39 of charges related to business optimization plans; including $36 for Health Benefits; $5 for Carelon Services; and a ($2) benefit for the Corporate & Other segment.

 

15

Elevance Health, Inc.

Financial Guidance Summary

(Unaudited)

 

     Full Year 2022 Actual   Full Year 2023 Outlook   Approximate
Change

Year-End Medical Enrollment

       

Fee-Based

    26,651   27,100 - 27,400   449k -749k

Risk-Based

    20,880   20,300 - 21,100   (580k)-220k
  

 

  

 

  

 

Total

    47,531   47,400 - 48,500   (131k) - 969k

Operating Revenue

    $155.7 billion   $164 billion   Approximately $8.3 billion
or 5.4%

Premium Revenue

    $133.2 billion   $140 billion   Approximately
$6.8 billion or 5.1%

Benefit Expense Ratio

    87.4%   87.2% +/- 50 bps   (20) bps +/- 50 bps

SG&A Expense Ratio

    11.4%   11.2% +/- 50 bps   (20) bps +/- 50 bps

Operating Gain

    $8.5 billion   Greater than $9.35 billion   Greater than $850 million
or 10.6%

Other Pre-Tax Items:

       

Net Investment income

    $1,485 million   $1,600 million   $115 million

Interest Expense

    ($851) million   ($1,000) million   ($149) million

Amortization of Intangible Assets

    ($767) million   ($869) million   ($102) million
  

 

  

 

  

 

Net Pre-Tax Expense

    ($133) million   ($269) million   ($136) million

Effective Tax Rate

    22.5%   22.0% - 24.0%   (0.5%) - 1.5%

GAAP EPS

    $24.81   Greater than $29.80   20.1% or better

Adjusted EPS

    $29.07   Greater than $32.60   12.1% or better

Diluted Shares

    242.8 million   239 - 240 million   (1.6%) - (1.2%)

Operating Cash Flow

    $8.4 billion   Greater than $7.6 billion   ($0.8) billion or better

Segment Level Guidance Metrics

       

Operating Revenue Growth Rate

       

Health Benefits

      Mid to upper single digit  

CarelonRx

      Upper single digit  

Carelon Services

      Low double digit  

Segment Operating Margin vs. 2022

       

Health Benefits

      Up 25-50 bps  

CarelonRx

      Unchanged  

Carelon Services

      Up 25-50 bps  

 

16

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not undertake to update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including healthcare laws and regulations, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or our failure to comply with any privacy or security laws or regulations, including any investigations, claims or litigation related thereto; information technology disruptions; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks associated with providing pharmacy benefit management (“PBM”), healthcare and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

 

17

EX-101.SCH 3 elv-20230125.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 elv-20230125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 elv-20230125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g418386dsp01a.jpg GRAPHIC begin 644 g418386dsp01a.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document and Entity Information
Jan. 25, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001156039
Document Type 8-K
Document Period End Date Jan. 25, 2023
Entity Registrant Name Elevance Health, Inc.
Entity Incorporation State Country Code IN
Entity File Number 001-16751
Entity Tax Identification Number 35-2145715
Entity Address, Address Line One 220 Virginia Ave
Entity Address, City or Town Indianapolis
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46204
City Area Code (833)
Local Phone Number 401-1577
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol ELV
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 8 d418386d8k_htm.xml IDEA: XBRL DOCUMENT 0001156039 2023-01-25 2023-01-25 false 0001156039 8-K 2023-01-25 Elevance Health, Inc. IN 001-16751 35-2145715 220 Virginia Ave Indianapolis IN 46204 (833) 401-1577 false false false false Common Stock ELV NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

"1J=Y MKD'*Z:01&!>^>T#HKBJZJU/H/LI4D(=-MA"F"037@&P_I_U!CR(\-*KM-#J% MZ(F_DKL$4DXN95P.VG&^%LE.[YS1;F] >QCA@>'34P@G20)F:,_>"^0>VI&O MJG$J6R09B\BS-"NI)">3+69GM/9]BMKV=YQ37].&/.E=\[:$RX$A2JYXKE-I M,;[:]RENW/_G*Q<% ,Z,WDI8BHV0N":Z*&B]%="3]H(*;::M@SWA3YD?7:PM MBMT^B[H86[T?4-S1BVF

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d418386d8k.htm d418386dex991.htm elv-20230125.xsd elv-20230125_lab.xml elv-20230125_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d418386d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d418386d8k.htm" ] }, "labelLink": { "local": [ "elv-20230125_lab.xml" ] }, "presentationLink": { "local": [ "elv-20230125_pre.xml" ] }, "schema": { "local": [ "elv-20230125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "elv", "nsuri": "http://www.elevancehealth.com/20230125", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d418386d8k.htm", "contextRef": "duration_2023-01-25_to_2023-01-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d418386d8k.htm", "contextRef": "duration_2023-01-25_to_2023-01-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.elevancehealth.com//20230125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-014676-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-014676-xbrl.zip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